These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16462497)

  • 1. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol.
    Abdel-Wahab M; Berkey BA; Krishan A; O'Brien T; Hammond E; Roach M; Lawton C; Pilepich M; Markoe A; Pollack A
    Am J Clin Oncol; 2006 Feb; 29(1):14-20. PubMed ID: 16462497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk.
    Bratt O; Borg A; Kristoffersson U; Lundgren R; Zhang QX; Olsson H
    Br J Cancer; 1999 Oct; 81(4):672-6. PubMed ID: 10574254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
    Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.
    Klotz L; Correia A; Zhang W
    Prostate Cancer Prostatic Dis; 2005; 8(2):179-83. PubMed ID: 15809670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor CAG polymorphism and prostate cancer risk.
    Mononen N; Ikonen T; Autio V; Rökman A; Matikainen MP; Tammela TL; Kallioniemi OP; Koivisto PA; Schleutker J
    Hum Genet; 2002 Aug; 111(2):166-71. PubMed ID: 12189490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Shimbo M; Suzuki H; Kamiya N; Imamoto T; Komiya A; Ueda T; Watanabe M; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Apr; 47(4):557-63. PubMed ID: 15774258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population.
    Silva Neto B; Koff WJ; Biolchi V; Brenner C; Biolo KD; Spritzer PM; Brum IS
    Cancer Invest; 2008 Feb; 26(1):74-80. PubMed ID: 18181049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
    Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
    J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population?
    Mishra D; Thangaraj K; Mandhani A; Kumar A; Mittal R
    Clin Genet; 2005 Jul; 68(1):55-60. PubMed ID: 15952987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients.
    Strom SS; Gu Y; Zhang H; Troncoso P; Babaian RJ; Pettaway CA; Shete S; Spitz MR; Logothetis CJ
    Prostate; 2004 Sep; 60(4):343-51. PubMed ID: 15264247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difference between Swedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene.
    Li C; Grönberg H; Matsuyama H; Weber G; Nordenskjöld M; Naito K; Bergh A; Bergerheim U; Damber JE; Larsson C; Ekman P
    Int J Mol Med; 2003 Apr; 11(4):529-33. PubMed ID: 12632109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter CAG repeat length in the AR gene is associated with poor outcome in head and neck cancer.
    Rosa FE; dos Santos RM; Poli-Frederico RC; Canevari Rde A; Nishimoto IN; Magrin J; Rainho CA; Kowalski LP; Rogatto SR
    Arch Oral Biol; 2007 Aug; 52(8):732-9. PubMed ID: 17321486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CAG microsatellite polymorphisms of androgen receptor gene and the stage and grade of prostate cancer].
    Li C; Dong J; Guan W
    Zhonghua Zhong Liu Za Zhi; 2001 May; 23(3):217-9. PubMed ID: 11783090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor polymorphisms and the incidence of prostate cancer.
    Chen C; Lamharzi N; Weiss NS; Etzioni R; Dightman DA; Barnett M; DiTommaso D; Goodman G
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1033-40. PubMed ID: 12376504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?
    Zeegers MP; Kiemeney LA; Nieder AM; Ostrer H
    Cancer Epidemiol Biomarkers Prev; 2004 Nov; 13(11 Pt 1):1765-71. PubMed ID: 15533905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.